Interestingly, the JAK1/2 inhibitor enhanced the growth inhibitory effect of the MEK-inhibitor, particularly in poorly immunogenic BRAF or KRAS mutant cancer cells (HT29 and SW620) (Fig. 5a). This evidence concerns the gene MAP2K7 and cancer.